School Of Medicine Basic Sciences
-
Immune research authority Robert Tampé to deliver Apex Lecture on March 7
Immune research authority Robert Tampé will present the Vanderbilt School of Basic Sciences Apex Lecture on March 7, 2024. Read MoreFeb. 21, 2024
-
Signal transduction authority Xuewu Zhang to deliver Apex Lecture on March 4
Signal transduction authority Xuewu Zhang to present the Vanderbilt School of Medicine Basic Sciences Apex Lecture on March 4, 2024. Read MoreFeb. 16, 2024
-
Immune research authority Robert Tampé to deliver Apex Lecture on March 7
Immune research authority Robert Tampé to present the Vanderbilt Basic Sciences Apex Lecture March 7. Read MoreFeb. 13, 2024
-
Signal transduction authority Xuewu Zhang to deliver Apex Lecture on March 4
Signal transduction authority Xuewu Zhang to present the Vanderbilt Basic Sciences Apex Lecture March 4. Read MoreFeb. 13, 2024
-
Combining unique methods, Kuriyan lab discovers new protein functions; explores physical space of proteins
Combining deep mutagenesis and cryo-EM reveals new conformational state of a protein responsible for high-speed DNA replication. The research builds on growing theories of molecular evolution. Read MoreFeb. 6, 2024
-
Destination Biochemistry welcomes Baris and Pollenz—and new applicants
Baris and Pollenz have been selected as the Danzo and Cohen Postdoctoral Scholars, respectively. Destination Biochemistry applications for the next cohort are due Thursday, Feb. 15. Read MoreFeb. 2, 2024
-
First successful clinical trial of VU319 brings Alzheimer’s treatment one step closer
Phase I clinical trial of a drug was successfully completed at the Warren Center for Neuroscience Drug Discovery, with promise to treat Alzheimer’s and other neurodegenerative diseases. The compound, named VU319, is the first Vanderbilt end-to-end drug discovery effort related to memory loss, starting from the earliest basic science research through human clinical trials. Read MoreJan. 19, 2024
-
Innovation Ignition Fund launches a pilot program to support early-stage therapeutic projects with translational viability
The School of Medicine Basic Sciences and the Office of the Vice Provost for Research and Innovation launch the Innovation Ignition Fund. This pilot program offers up to $500,000 in funding and drug development mentorship from Vanderbilt scientists with expertise in translational research. Read MoreJan. 8, 2024
-
Study uses new tools, machine learning to investigate major cause of blindness in older adults
An international collaboration led by Vanderbilt researchers has identified a key component in lesions associated with age-related macular degeneration (AMD), a leading cause of blindness in older adults. Read MoreDec. 20, 2023
-
Potential schizophrenia treatment, discovered at Vanderbilt and being developed by Neumora Therapeutics, entering Phase 1 clinical trial
A potential schizophrenia treatment discovered through the Warren Center for Neuroscience Drug Discovery has been cleared by the U.S. Food and Drug Administration for use in phase 1 clinical trials—the third WCNDD therapeutic to reach that benchmark. “Vanderbilt is proud that a discovery by our researchers at the Warren Center… Read MoreDec. 4, 2023